Citius Oncology, Inc. Common Stock (CTOR)

• Market cap: $83.7M
• 1 day: -2.50%
• 5 days: -8.59%
• 1 month: -4.10%
• 3 months: 19.89%
• 6 months: -39.38%
• Year to date: -1.68%
• 1 year: -89.41%
• 5 years: -88.40%
• 10 years: -88.40%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

304% more capital invested

Capital invested by funds: $57K [Q3] → $230K (+$173K) [Q4]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

57% more funds holding

Funds holding: 7 [Q3] → 11 (+4) [Q4]

0.22% more ownership

Funds ownership: 0.06% [Q3] → 0.28% (+0.22%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 156% upside
• Avg. target: $3 156% upside
• High target: $3 156% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Michael Okunewitch 44% 1-year accuracy 4 / 9 met price target

156% upside $3

Buy Initiated

27 Nov 2024